Efficacy of meaning-centered group psychotherapy in Chinese patients with cancer: A randomized controlled trial.

Objectives: Meaninglessness is one of the most common psychological problems in cancer patients, which can lead to anxiety, depression and psychological distress, and diminished quality of life. Recent evidence indicates that meaning-centered group psychotherapy (MCGP) effectively enhances the meaning in life among cancer patients. This study aimed to evaluate the impact of MCGP on the meaning in life, post-traumatic growth, psychological distress, and fear of recurrence among Chinese cancer patients with a favorable prognosis.

Clinical features and prognosis of patients with metastatic ocular and orbital melanoma: A bi-institutional study.

Purpose: Metastatic ocular and orbital melanomas are extremely rare. The clinical characteristics and standard treatments for these patients are not fully established.

Materials And Methods: We retrospectively analyzed patients with metastatic ocular and orbital melanoma from Fudan University Shanghai Cancer Center and Eye & ENT Hospital of Fudan University between January 2012 and May 2022.

evaluation of photon and carbon ion radiotherapy in combination with cisplatin in head and neck squamous cell carcinoma cell lines.

Background: Heavy ion radiotherapy, such as carbon ion radiotherapy (CIRT), has multiple advantages over conventional photon therapy. Cisplatin, as a classic anti-tumor drugs, has been tested and discovered as a photon radiosensitizer in several cell lines, including head and neck squamous cell carcinoma (HNSCC). Hence, the aim of our study is to evaluate whether cisplatin can sensitize CIRT towards HNSCC cell lines .

Applying multisequence MRI radiomics of the primary tumor and lymph node to predict HPV-related p16 status in patients with oropharyngeal squamous cell carcinoma.

Background: Human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) is currently rising in incidence; however, a noninvasive approach to predicting HPV status that strongly correlates with p16 expression is lacking. This study aimed to develop a radiomics model based on multisequence magnetic resonance imaging (MRI) of primary tumor (PT) and lymph node (LN)-fused imaging features for the prediction of p16 status in OPSCC.

Methods: In this retrospective study, 141 patients (comprising 116 patients in the training cohort and 25 patients in the testing cohort) with histopathologically confirmed (OPSCC) were enrolled consecutively from Fudan University Shanghai Cancer Center and Shanghai Ninth People's Hospital between January 2011 and December 2020.

Preliminary clinical outcomes of head and neck squamous cell carcinoma treated with particle beam radiation therapy.

Purpose: Further improvement in clinical outcomes is needed for patients with head and neck squamous cell carcinoma (HNSCC), as there is typically a poor prognosis at diagnosis. This study aimed to report the preliminary therapeutic outcomes and side effects in patients with HNSCC receiving particle beam radiotherapy (PBRT), owing to the physical and biological advantages of this approach.

Methods: We retrospectively analyzed 68 patients with newly diagnosed HNSCC who received PBRT at the Shanghai Proton and Heavy Ion Center (SPHIC) between August 2015 and December 2020.

A retrospective study of adjuvant proton radiotherapy for breast cancer after lumpectomy: a comparison of conventional-dose and hypofractionated dose.

Purpose: This study aimed to compare the adverse reactions of conventional-dose and hypofractionated dose of proton therapy for breast cancer.

Materials And Methods: Breast cancer patients treated with proton radiotherapy in conventional-dose or hypofractionated dose were studied retrospectively.

Result: From January 2017 to December 2019, our center treated 50 patients following lumpectomy with proton radiotherapy.

Utilization of Diaphragm Motion to Predict the Displacement of Liver Tumors for Patients Treated with Carbon ion Radiotherapy.

To establish and validate a linear model utilizing diaphragm motion (DM) to predict the displacement of liver tumors (DLTs) for patients who underwent carbon ion radiotherapy (CIRT). A total of 60 pairs of planning and reviewing four-dimensional computed tomography (4DCT) sets over 23 patients were used. We constructed an averaged computed tomography (CT) set for each either planning or reviewing 4DCT within respiratory phases between 20% of exhale and inhale.

Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation.

The recently described role of RNA methylation in regulating immune cell infiltration into tumors has attracted interest, given its potential impact on immunotherapy response. YTHDF1 is a versatile and powerful m6A reader, but the understanding of its impact on immune evasion is limited. Here, we reveal that tumor-intrinsic YTHDF1 drives immune evasion and immune checkpoint inhibitor (ICI) resistance.

Classification of solid pulmonary nodules using a machine-learning nomogram based on F-FDG PET/CT radiomics integrated clinicobiological features.

Background: To develop and validate an F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) and clinico-biological features-based nomogram for distinguishing solid benign pulmonary nodules (BPNs) from malignant pulmonary nodules (MPNs).

Methods: A total of 280 patients with BPN (n=128) or MPN (n=152) were collected retrospectively and randomized into the training set (n=196) and validation set (n=84). Pretherapeutic clinicobiological markers, PET/CT metabolic features and radiomic features were analyzed and selected to develop prediction models by the machine-learning method [Least Absolute Shrinkage and Selection Operator (LASSO) regression].

Higher aorta dose increased neutrophil-to-lymphocyte ratio resulting in poorer outcomes in stage II-III non-small cell lung cancer.

Background: This study focused on the relationship between the neutrophil-to-lymphocyte ratio (NLR) and the dose of organs at risk in patients with stage II-III non-small cell lung cancer (NSCLC) receiving intensity-modulated radiotherapy.

Methods: The clinical characteristics and dosimetric parameters of 372 patients were collected retrospectively. A high NLR was defined as that ≥1.

Calibration and evaluation of the relative biological effectiveness for carbon-ion radiotherapy in a new relative to a clinically applied treatment planning system.

Background: The study objective was to validate the relative biological effectiveness (RBE) in RayStation for carbon-ion radiotherapy (CIRT) using the Syngo treatment planning system as reference.

Methods: Local effect model I was established in RayStation (Ray-LEM) with the same parameters as in LEM I in Syngo (Syngo-LEM). Three cube plans covering most of the tumors treated at our center were generated with Syngo-LEM.

Proton and Carbon Ion Radiation Therapy Decreased Severe Lymphopenia by Reducing Thoracic Vertebra and Aortic Doses in Non-Small Cell Lung Cancer Versus Intensity Modulated Radiation Therapy.

Purpose: Lymphopenia is a common adverse effect of radiation therapy (RT). Little is known about the difference in lymphopenia between intensity modulated (photon) radiation therapy (IMRT) and proton and carbon ion radiation therapy (PCIRT). This study aimed to investigate lymphopenia differences between IMRT and PCIRT in non-small cell lung cancer (NSCLC).

Proton radiotherapy in the treatment of IDH-mutant diffuse gliomas: an early experience from shanghai proton and heavy ion center.

Purpose: According to the presence or absence of isocitrate dehydrogenase (IDH) mutation, the 2021 WHO classification system bisected diffuse gliomas into IDH-mutant tumors and IDH-wildtype tumors. This study was aimed to evaluate the outcomes of proton radiotherapy treating IDH-mutant diffuse gliomas.

Patients And Methods: Between May 2015 and May 2022, a total of 52 consecutive patients with IDH-mutant diffuse gliomas were treated at Shanghai Proton and Heavy Ion Center.

Carbon-ion radiotherapy in the treatment of radiation-induced second primary malignancies.

Background: Treatment of radiation-induced second primary malignancy (RI-SPM) is challenging and usually associated with poor outcomes. For patients with unresectable or incompletely resected diseases, carbon-ion radiotherapy (CIRT) offers physical and biologic advantages over photon-based re-irradiation. We report the results of salvage CIRT in 15 patients with RI-SPM.

A cross-sectional analysis of registered clinical trials on the use of particle beam radiation therapy in head and neck cancers.

Background: To present and analyze the current status of registered clinical trials on particle beam (including proton and carbon ion beam) radiation therapy (PBRT) for head and neck (H&N) malignancies, and to provide insights for future clinical research, we designed the cross-sectional analysis.

Methods: We identified and analyzed all clinical trials of interest registered on ClinicalTrials.gov and PTCOG.

Particle beam radiation therapy for head and neck rhabdomyosarcoma in adults.

Background: Rhabdomyosarcoma (RMS) is rare in adults, with a significantly worse prognosis than its pediatric counterpart. Radiotherapy (RT) plays a significant role in treating head and neck RMS (HNRMS), but the outcomes of conventional RT are limited by the complex anatomy and unfavorable pathology subtypes of the adult H&N RMS. Here, we aim to report the effectiveness and safety of carbon-ion beam RT (CIRT), either alone or in combination with proton radiotherapy (PRT) in the management of adult HNRMS.

Perfusion MR prior to radiotherapy is a strong predictor of survival in high-grade gliomas after proton and carbon ion radiotherapy.

Background: To assess the survival predictability of perfusion magnetic resonance imaging (MRI) by the normalized cerebral blood volume (nCBV) prior to particle beam radiotherapy (PBRT) in high-grade glioma (HGG) patients underwent particle therapy.

Methods: The study retrieved dynamic susceptibility contrast MRI acquired prior to PBRT between 6/2015 and 3/2019 in 45 patients with HGG. Maximum nCBV (nCBVmax) within or adjacent to surgical/tumor bed was measured using 'hot-spot' method.

The role of carbon-ion radiotherapy in the treatment of adenoid cystic carcinoma of the nasopharynx.

Background: Nasopharyngeal adenoid cystic carcinoma (NACC) is a distinct subgroup of adenoid cystic carcinoma (ACC) with limited surgical access but predilection of regional and distant metastasis. Although radiotherapy is an integral treatment for patients with NACC, photon-based radiotherapy yielded suboptimal local control. Because of its advantages in biology and physics properties, carbon-ion radiotherapy (CIRT) was attempted for the treatment of head and neck ACC; however, the use of CIRT specifically for NACC has not been investigated.

Intensity-modulated proton and carbon-ion radiation therapy in the management of major salivary gland carcinomas.

Background: Primary major salivary gland carcinomas (SGCs) present with diverse histological types that are known to be largely radioresistant with a high tendency to develop distant metastasis (DM). Photon-based radiotherapy (RT) is limited in terms of its therapeutic effect and toxicities. In view of the physical and biological advantages of intensity-modulated proton and/or carbon-ion radiation therapy, we aimed to evaluate the short-term therapeutic effect and toxicities in patients with major SGCs treated with this form of radiation therapy.

Carbon-ion radiotherapy boost with standard dose proton radiation for incomplete-resected high-grade glioma: a phase 1 study.

Background: To investigate the maximal tolerated dose (MTD) of a carbon-ion radiotherapy (CIRT) boost prior to standard dose proton radiotherapy (PRT) for newly diagnosed glioblastoma (GBM) and anaplastic astrocytoma (AA) patients with residual lesion after resection.

Methods: In total, 18 patients with high-grade glioma (HGG) (16 with GBM and 2 with AA) were enrolled in a prospective 3×3 design phase 1 trial. We investigated four dose-levels of CIRT boost [9 (starting level), 12, 15, and 18 Gy relative biological effectiveness (RBE)] delivered in three equal fractions prior to the standard dose PRT (60 Gy RBE in 30 fractions).